What is HC Wainwright’s Estimate for Ocugen FY2025 Earnings?

Ocugen, Inc. (NASDAQ:OCGN) – Analysts at HC Wainwright decreased their FY2025 earnings estimates for shares of Ocugen in a research note issued on Thursday, November 6th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings per share of ($0.23) for the year, down from their prior forecast of ($0.20). The consensus estimate for Ocugen’s current full-year earnings is ($0.20) per share. HC Wainwright also issued estimates for Ocugen’s Q4 2025 earnings at ($0.06) EPS, Q1 2026 earnings at ($0.07) EPS, Q2 2026 earnings at ($0.07) EPS, Q3 2026 earnings at ($0.07) EPS, Q4 2026 earnings at ($0.08) EPS, FY2026 earnings at ($0.29) EPS, FY2027 earnings at ($0.18) EPS, FY2028 earnings at $0.08 EPS and FY2029 earnings at $0.84 EPS.

A number of other research analysts have also issued reports on OCGN. Chardan Capital restated a “buy” rating and issued a $7.00 target price on shares of Ocugen in a report on Friday, September 19th. Weiss Ratings reissued a “sell (e+)” rating on shares of Ocugen in a research note on Wednesday, October 8th. Finally, Wall Street Zen upgraded shares of Ocugen from a “sell” rating to a “hold” rating in a research report on Saturday, September 20th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Ocugen has a consensus rating of “Hold” and an average target price of $7.00.

Ocugen Stock Down 1.4%

OCGN opened at $1.36 on Monday. The firm has a market cap of $424.76 million, a P/E ratio of -6.80 and a beta of 4.15. The business’s fifty day simple moving average is $1.45 and its 200 day simple moving average is $1.13. Ocugen has a 52 week low of $0.52 and a 52 week high of $1.90. The company has a quick ratio of 1.83, a current ratio of 1.83 and a debt-to-equity ratio of 9.18.

Ocugen (NASDAQ:OCGN) last posted its earnings results on Wednesday, November 5th. The company reported ($0.07) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.01). Ocugen had a negative net margin of 1,197.71% and a negative return on equity of 255.25%. The firm had revenue of $1.75 million during the quarter, compared to analyst estimates of $0.44 million.

Institutional Investors Weigh In On Ocugen

Institutional investors have recently bought and sold shares of the stock. Nuveen LLC purchased a new position in Ocugen during the first quarter worth approximately $535,000. Procyon Advisors LLC purchased a new stake in shares of Ocugen during the 2nd quarter valued at $194,000. Northwestern Mutual Wealth Management Co. acquired a new stake in shares of Ocugen during the 1st quarter worth $28,000. GSA Capital Partners LLP raised its position in shares of Ocugen by 43.0% in the 1st quarter. GSA Capital Partners LLP now owns 1,638,033 shares of the company’s stock worth $1,157,000 after buying an additional 492,300 shares during the period. Finally, GMT Capital Corp raised its position in shares of Ocugen by 69.2% in the 1st quarter. GMT Capital Corp now owns 4,153,798 shares of the company’s stock worth $2,934,000 after buying an additional 1,698,840 shares during the period. 10.27% of the stock is currently owned by hedge funds and other institutional investors.

About Ocugen

Ocugen, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients’ health. The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.